MSI appoints new partner

pharmafile | April 16, 2012 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing MSI Consultancy, Sanofi, appointment 

Pharma consultancy firm MSI has announced the appointment of a new partner. 

Steve Mather takes up this senior position with many years’ experience in pharma. 

He was most recently core brands business unit director for Sanofi in the UK, responsible for sales and marketing of the promoted portfolio. 

In 17 years with the company, he built an impressive track record in a variety of sales, marketing and business ownership roles, including significant experience in global marketing. 

Advertisement

Prior to joining Sanofi, Steve worked for Serono and Rhone-Poulenc Rorer.

MSI’s managing director Jon Bircher, said: “I am delighted to welcome Steve into MSI’s leadership team as Partner. Steve is an experienced leader with significant pharmaceutical sales and marketing experience in both UK and international roles. 

“He has tackled challenges across all stages of the lifecycle with specialty and primary care brands at operational and strategic levels and as a consultant is already demonstrating how this experience, expertise and fresh perspective adds value to our clients.

“This appointment represents another significant step forward in our global growth plans and continues to enhance our growing international consultancy team,” Bircher added.

Related Content

Sanofi and Regeneron’s Dupixent receives CHMP recommendation for chronic spontaneous urticaria

Sanofi and Regeneron have received a positive opinion from the European Medicines Agency’s (EMA) Committee …

Sanofi’s treatment granted orphan designation for rare chronic inflammatory condition

The European Medicines Agency has granted orphan designation to Sanofi’s investigational Bruton’s tyrosine kinase (BTK) …

sanofi

Sanofi completes acquisition of Vigil Neuroscience to early neurology pipeline

Sanofi has announced that it has finalised its acquisition of Vigil Neuroscience, a US-based biotechnology …

The Gateway to Local Adoption Series

Latest content